Abstract

The long-term goal of this application is to provide stable research funding for a Cancer Pharmacokinetics Research Specialist within the University of Pittsburgh Cancer Institute (UPCI) Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF). The activities of the Cancer Pharmacokinetics Research Specialist can be categorized broadly into: (1) Pharmacokinetic assay development and validation; (2) Preclinical pharmacokinetics; and (3) Clinical pharmacokinetics. The Cancer Pharmacokinetics Research Specialist plays an absolutely critical role in developing and validating novel LC-MS/MS methodologies, and applying them to precisely delineate the PK and metabolism of novel and established agents. The stated new research directions of: (1) generic assay platform development; (2) metabolite structural elucidation by high-resolution mass spectrometer; and (3) population-pharmacokinetic analyses of clinical pharmacokinetic data, are relevant and sure to enhance the research output of the CPPF. This award will allow the CPPF Cancer Pharmacokinetics Research Specialist to continue to be at the cutting edge, with the ultimate aim of serving the scientific community in early drug development needs.

Public Health Relevance

The Cancer Pharmacokinetics Research Specialist will support the development of new anticancer agents by pharmacokinetic assay development and validation, preclinical and clinical pharmacokinetics, thus serving the scientific community in early drug development needs which will lead to enhancement of patient care and treatment outcome.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Project #
1R50CA211241-01
Application #
9220864
Study Section
Special Emphasis Panel (ZCA1-SRB-V (A1))
Program Officer
Ivy, S Percy
Project Start
2016-09-15
Project End
2021-08-31
Budget Start
2016-09-15
Budget End
2017-08-31
Support Year
1
Fiscal Year
2016
Total Cost
$178,644
Indirect Cost
$62,923

  Institution

Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213

  Publications

Liu, Haizhou; Liu, Hui; Zhou, Zhiyi et al. (2018) Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway. Cell Commun Signal 16:7
Singh, Renu; Mehrotra, Shailly; Gopalakrishnan, Mathangi et al. (2018) Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemother Pharmacol :
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Leibowitz, Brian J; Yang, Liheng; Wei, Liang et al. (2018) Targeting p53-dependent stem cell loss for intestinal chemoprotection. Sci Transl Med 10:
Vendetti, Frank P; Karukonda, Pooja; Clump, David A et al. (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128:3926-3940
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Benoist, Guillemette E; van der Meulen, Eric; Lubberman, Floor J E et al. (2017) Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. Biomed Chromatogr 31:
Matsumoto, Julia; Kiesel, Brian F; Parise, Robert A et al. (2017) LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. J Pharm Biomed Anal 146:154-160
Kiesel, Brian F; Shogan, Jeffrey C; Rachid, Madani et al. (2017) LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma. J Pharm Biomed Anal 138:158-165
Kim, Kyu-Pyo; Parise, Robert A; Holleran, Julianne L et al. (2017) Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. J Pharm Biomed Anal 138:197-205

Showing the most recent 10 out of 11 publications